Format:
Online-Ressource
,
v.: digital
Edition:
Online-Ausg. Springer eBook Collection. Medicine Electronic reproduction; Available via World Wide Web
ISBN:
9781617794070
Series Statement:
Current Clinical Oncology
Content:
Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas - over-exposure to ultraviolet light - is well known, effective treatment has remained challenging. The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal t
Note:
Description based upon print version of record
,
Targeted Therapeuticsin Melanoma; Preface; Cracking the Melanoma Nut; Acknowledgments; Contents; Contributors; Part I: Advances in Melanoma Biology; Chapter 1: Molecular Targets and Subtypes in Melanoma; Introduction; BRAF; NRAS; PI3K-AKT Pathway; c-KIT; GNAQ; Conclusions; References; Chapter 2: Melanoma Genomics; Gene Expression Profiling of Distinct Phases of Melanoma Progression; Gene Expression Profiles of Primary Melanoma; Gene Expression Profiling of Metastatic Melanoma; Conclusions; References; Chapter 3: Predictive Biomarkers as a Guide to Future Therapy Selection in Melanoma
,
Evidence for Existence of Biologic Subsets of MelanomaKinase Mutations and Clinical Response to Kinase Inhibitors; B-Raf; c-kit; New Pathways Showing Heterogeneity Among Individual Melanoma Patients; Gene Expression Profiling and Clinical Response to Melanoma Vaccines; Molecular Features Associated with Response to Chemotherapy; Biomarkers as a Tool to Determine Mechanisms of Therapeutic Resistance; Predictive Biomarkers from Non-Tumor Tissue: Serum and Germline DNA; The Evolving Future of Melanoma Therapy; References; Part II: Signaling Molecules as Molecular Targets
,
Chapter 4: KIT as a Therapeutic Target for MelanomaIntroduction; KIT as a Proto-Oncogene; The Role of KIT in Cancer; KIT Tyrosine Kinase Inhibitors; Overcoming Resistance to Tyrosine Kinase Inhibition; Is KIT Amplification or Mutation More Important?; Conclusions; References; Chapter 5: Targeted Inhibition of B-Raf; Introduction; The MAPK Pathway; BRAF Mutations in Melanoma; Preclinical Studies; RAF Inhibition of BRAF Wild-Type Cells Leads to Activation of the MAPK Pathway; RAF Inhibition of BRAF-Mutated Melanoma Causes Melanoma Cell Death
,
Clinical Studies with the RAF Inhibitor PLX4032 (RO5185426)Spectrum of BRAF Inhibitors in Clinical Trials; MEK Inhibition as a Strategy for Targeting BRAF Mutant Melanoma; Resistance Mechanisms Observed in Clinical Trials; Future Directions for BRAF Inhibitors; References; Chapter 6: The Notch and b -Catenin Pathways; Notch Signaling; Notch and Cancer; Targeting Notch in Melanoma; b -catenin Signaling; Wnt/ b -catenin and Cancer; Targeting b -catenin in Melanoma; Perspective; References; Chapter 7: STAT3 and Src Signaling in Melanoma; Introduction; STAT3 and Src Signaling in Melanoma
,
STAT3/Src Regulation of Tumor Cell GrowthSTAT3 and Src Activity Promote Angiogenesis and Metastasis in Melanoma; STAT3 Signaling in Tumor-Associated Immune Cells: Their Role in Melanoma Development; Treatment of Melanoma by STAT3-Targeted Therapy; Inhibition of STAT3 Activation in Melanoma via Small-Molecule Inhibitors; Conclusions; References; Chapter 8: Targeting the mTOR, PI3K, and AKT Pathways in Melanoma; mTor Overview: Normal Functions and Genetic Alterations of Importance in Melanoma; Upstream Effectors of mTOR Activation: PTEN, PI3K, and AKT
,
mTOR Complexes and Downstream Events: Control of Transcription
,
Electronic reproduction; Available via World Wide Web
Additional Edition:
9781617794063
Language:
English
DOI:
10.1007/978-1-61779-407-0
URL:
Volltext
(lizenzpflichtig)
Bookmarklink
